Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 17 (9), 68

New Therapeutic Strategies for Lewy Body Dementias

Affiliations
Review

New Therapeutic Strategies for Lewy Body Dementias

Latha Velayudhan et al. Curr Neurol Neurosci Rep.

Abstract

This article reviews current treatment strategies and recent advances for the Lewy body dementias (LBDs). Current available symptom treatment strategies are based on monoaminergic, cholinergic and glutaminergic neurotransmitter systems. Relatively robust evidence exists for cholinesterase inhibitors for cognitive impairment in LBD and in Parkinson's disease for antidepressants, clozapine and recently pimavanserin for psychosis. interpidine (RVT 101) and nelotanserin are currently under investigation. Non-pharmacological interventions, such as cognitive stimulation, physical exercises and neuromodulation strategies, may be useful in Parkinson's disease but have not yet been tested in dementias. Disease-modifying approaches are aimed at preventing, slowing or ameliorating the production, aggregation and deposition of pathological proteins, including immunotherapy targeting α-synuclein and an ongoing trial using ambroxol which increases glucocerebrosidase activity to lower the levels of the protein alpha-synuclein. Other disease-modifying clinical trials are using agents to augment insulin signalling, stem cell therapy, reducing amyloid pathology and gene therapy.

Keywords: Dementia with Lewy bodies; Lewy body dementia; Parkinson’s disease; Therapy; Treatment; α-synuclein.

Similar articles

See all similar articles

Cited by 4 PubMed Central articles

References

    1. Mov Disord. 2016 Feb;31(2):225-34 - PubMed
    1. Acta Neuropathol. 2014;127(6):861-79 - PubMed
    1. Mov Disord. 2015 Oct;30(12 ):1657-63 - PubMed
    1. Sleep Med. 2013 Mar;14(3):237-42 - PubMed
    1. Dement Geriatr Cogn Disord. 2013;36(3-4):229-41 - PubMed

MeSH terms

LinkOut - more resources

Feedback